EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience
复制标题
DOI：
10.1182/blood-2011-10-388967
复制
发表时间：
2012-05-10
期刊：
影响因子：
20.3
通讯作者：
Kantarjian, Hagop
中科院分区：
文献类型：
--
作者：
Jabbour, Elias;Cortes, Jorge;Kantarjian, Hagop
为了验证最近报告的欧洲治疗和结果研究 (EUTOS) 评分，我们将其应用于 465 名接受标准剂量伊马替尼 (n = 71)、高剂量伊马替尼 (n = 208) 或第二代酪氨酸激酶抑制剂 (n = 186) 治疗的早期慢性期慢性粒细胞白血病患者，并评估其预测无事件生存 (EFS)、无转化生存的能力（TFS）和总生存期（OS）。中位随访时间为 69 个月。总体完全细胞遗传学缓解率和主要分子缓解率分别为 92% 和 85%。 3 年 EFS、TFS 和 OS 率分别为 86%、95% 和 97%。在 465 名患者中，427 名 (92%) 属于低 EUTOS 评分类别。 EUTOS 评分低和高的患者之间的主要分子缓解、TFS、EFS 和 OS 率（整体和特定治疗中）没有差异。总之，在我们机构治疗的慢性期慢性粒细胞白血病患者中有 8% 处于高 EUTOS 评分；在该人群中，EUTOS 评分不能预测结果。 （血。2012；119（19）：4524-4526）
To validate the recently reported European Treatment and Outcomes Study (EUTOS) score, we applied it to 465 patients with early chronic phase chronic myeloid leukemia treated with standard-dose imatinib (n = 71), high-dose imatinib (n = 208), or second-generation tyrosine kinase inhibitors (n = 186), and assessed its ability to predict event-free survival (EFS), transformation-free survival (TFS), and overall survival (OS). The median follow-up was 69 months. The overall complete cytogenetic response and major molecular response rates were 92% and 85%, respectively. The 3-year EFS, TFS, and OS rates were 86%, 95%, and 97%, respectively. Of the 465 patients, 427 (92%) were in low EUTOS score category. There was no difference in the major molecular response, TFS, EFS, and OS rates between patients with low and high EUTOS score, overall and within specific therapies. In conclusion, 8% of patients with chronic phase chronic myeloid leukemia treated at our institution are in the high EUTOS score; in this population, the EUTOS score was not predictive for outcome. (Blood. 2012; 119(19): 4524-4526)